After-Hours Movers 12/07: THLD, FLWS, ARIA, FDX Higher; FMCN, PBY, TCAP, CACB, CASY Lower
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) 8.9% HIGHER; announced preclinical results related to Threshold's clinical stage hypoxia-activated prodrug, TH-302. The study found that almost all of the MM cells in the model reside in a hypoxic environment in the bone marrow and that these tumor cells may be a target for tumor-specific treatment with TH-302. In vivo, animals treated prophylactically with TH-302 showed decreased serum paraprotein compared to those not treated with TH-302. The frequency of apoptotic MM cells in bone marrow sections was also significantly increased in animals treated with TH-302. In vitro, 5T33 cell-based assays demonstrated TH-302 induces cell cycle arrest and triggers apoptosis in an oxygen concentration-dependent manner. Taken together, these results support continued investigation with TH-302 as a potential treatment for multiple myeloma. Click here for the full report.
1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) 7.4% HIGHER; today reported that it has signed a definitive letter of agreement to sell its Home and Childrens Gifts business to PH International, LLC, a Richmond, Virginia-based manufacturer and wholesaler of home décor and garden products. Included in the sale are the Plow and Hearth, Problem Solvers, Wind and Weather, HearthSong and Magic Cabin brands as well as the divisions offices and warehouse facility in Madison, VA and a warehouse distribution center located in Vandalia, OH. According to the terms of the agreement, purchase price is $17 million (plus adjustments for seasonal working capital). The sale is expected to close near the end of January, 2010.
Focus Media Holding Ltd. (Nasdaq: FMCN) 7.2% LOWER; reports Q3 loss of $0.99, which does not compare to the analyst estimate of $0.12. Non-GAAP net income was $7.9 million. Revenue for the quarter was $166.6 million, which compares to the estimate of $ million.
Pep Boys (NYSE: PBY) 6.2% LOWER; reports Q3 EPS of $0.04, inline the analyst estimate of $0.04. Revenue for the quarter was $472.6 million, which compares to the estimate of $468.51 million. Comps were up 1.6%.
Triangle Capital Corporation (Nasdaq: TCAP) 6.1% LOWER; announced the commencement of a public offering of 1,300,000 shares of common stock in an underwritten public offering. The Company also plans to grant the underwriters a 30-day option to purchase up to an additional 195,000 shares of its common stock to cover over-allotments, if any. The Company intends to invest the net proceeds of this public offering in lower middle market companies in accordance with its investment objective and strategies, and for working capital and general corporate purposes.
Cascade Bancorp (NASDAQ: CACB) 4.9% LOWER; announced today that it has commenced an offering of approximately $93 million of its common stock in an underwritten public offering through Keefe, Bruyette & Woods, Inc. and Macquarie Capital (USA) Inc. The Company intends to grant the underwriters a 30 day option to purchase up to an additional 15% of the common stock sold in the offering to cover over-allotments, if any.
Casey's General Stores (NASDAQ: CASY) 4.8% LOWER; reports Q2 EPS of $0.66, 6 cents better than the analyst estimate of $0.60. Revenue for the quarter was $1.15 billion, which compares to the estimate of $1.20 billion. Comps up 1.9%.
Celgene International Sàrl (NASDAQ: CELG) 4.8% LOWER; announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma. Patients were treated with REVLIMID and dexamethasone for nine four-week cycles and then continued treatment with a lower dose of REVLIMID to sustain disease control until progression. The results showed an overall response rate of 81%, including 30% with a very good partial response or better. For the patients who completed the initial nine treatment cycles, the overall response rate was 91%. After a median follow-up of 14 months, disease progression was observed in two patients (4%) treated with REVLIMID and dexamethasone, while sixteen (34%) patients progressed to active myeloma in the arm with no treatment. Ten out of 16 of those patients also developed bone lesions due to active myeloma. It was noted that the two patients who progressed after receiving REVLIMID and dexamethasone progressed only after stopping therapy with REVLIMID.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) 4.5% HIGHER; today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia, including those with the T315I mutation of the target protein, BCR-ABL. Click here to see more details.
Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) 4.3% LOWER; announced today the commencement of an underwritten public offering of 3,000,000 common units. Calumet also intends to grant the underwriters the option to purchase up to 450,000 additional common units.
Select Comfort Corporation (NASDAQ: SCSS) 4.1% LOWER; today announced that the company intends to offer shares of its common stock via an underwritten public offering. Piper Jaffray is acting as the sole manager for the underwritten public offering. The company plans to use the proceeds of the public offering to improve working capital and pay down debt.
FedEx (NYSE: FDX) 3.1% HIGHER; raises Q2 EPS guidance from $0.65-$0.95 to $1.10. Click here to see the full report.
Kimco Realty Corporation (NYSE: KIM) 2.8% LOWER; announced that it plans to sell 25,000,000 shares of newly issued common stock in an underwritten public offering pursuant to its effective shelf registration statement previously filed with the Securities and Exchange Commission. The underwriters will be granted a 30-day option to purchase up to an additional 3,750,000 shares to cover over-allotments, if any.
UPS (NYSE: UPS) 2.4% HIGHER; moving higher amid the FedEx raised guidance.
Diedrich Coffee, Inc.’s (NASDAQ: DDRX) 2.3% LOWER; Peet’s Coffee & Tea, Inc. (NASDAQ: PEET) announced today that in response to determination that the most recent proposal from Green Mountain Coffee Roasters, Inc. (NASDAQ: GMCR) to acquire Diedrich was superior to Peet’s most recent proposal, Peet’s will not further enhance its proposal. Peet’s further announced that it will leave in place its exchange offer to acquire Diedrich for a combination of cash and stock valued at $26.00 per share. Click here for the full report.
ModusLink Global Solutions, Inc. (NASDAQ: MLNK) 1.1% LOWER; reports Q1 EPS of $0.19, compared to ($0.41) in the same quarter last year. Revenue for the quarter was $246.68 billion, which compares to $291.42 million for Q109.
To get this report daily, visit http://www.streetinsider.com/entities/After-Hours+Movers.
1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS) 7.4% HIGHER; today reported that it has signed a definitive letter of agreement to sell its Home and Childrens Gifts business to PH International, LLC, a Richmond, Virginia-based manufacturer and wholesaler of home décor and garden products. Included in the sale are the Plow and Hearth, Problem Solvers, Wind and Weather, HearthSong and Magic Cabin brands as well as the divisions offices and warehouse facility in Madison, VA and a warehouse distribution center located in Vandalia, OH. According to the terms of the agreement, purchase price is $17 million (plus adjustments for seasonal working capital). The sale is expected to close near the end of January, 2010.
Focus Media Holding Ltd. (Nasdaq: FMCN) 7.2% LOWER; reports Q3 loss of $0.99, which does not compare to the analyst estimate of $0.12. Non-GAAP net income was $7.9 million. Revenue for the quarter was $166.6 million, which compares to the estimate of $ million.
Pep Boys (NYSE: PBY) 6.2% LOWER; reports Q3 EPS of $0.04, inline the analyst estimate of $0.04. Revenue for the quarter was $472.6 million, which compares to the estimate of $468.51 million. Comps were up 1.6%.
Triangle Capital Corporation (Nasdaq: TCAP) 6.1% LOWER; announced the commencement of a public offering of 1,300,000 shares of common stock in an underwritten public offering. The Company also plans to grant the underwriters a 30-day option to purchase up to an additional 195,000 shares of its common stock to cover over-allotments, if any. The Company intends to invest the net proceeds of this public offering in lower middle market companies in accordance with its investment objective and strategies, and for working capital and general corporate purposes.
Cascade Bancorp (NASDAQ: CACB) 4.9% LOWER; announced today that it has commenced an offering of approximately $93 million of its common stock in an underwritten public offering through Keefe, Bruyette & Woods, Inc. and Macquarie Capital (USA) Inc. The Company intends to grant the underwriters a 30 day option to purchase up to an additional 15% of the common stock sold in the offering to cover over-allotments, if any.
Casey's General Stores (NASDAQ: CASY) 4.8% LOWER; reports Q2 EPS of $0.66, 6 cents better than the analyst estimate of $0.60. Revenue for the quarter was $1.15 billion, which compares to the estimate of $1.20 billion. Comps up 1.9%.
Celgene International Sàrl (NASDAQ: CELG) 4.8% LOWER; announced that data evaluating combination therapy REVLIMID (lenalidomide) and dexamethasone in patients with high-risk smoldering multiple myeloma. Patients were treated with REVLIMID and dexamethasone for nine four-week cycles and then continued treatment with a lower dose of REVLIMID to sustain disease control until progression. The results showed an overall response rate of 81%, including 30% with a very good partial response or better. For the patients who completed the initial nine treatment cycles, the overall response rate was 91%. After a median follow-up of 14 months, disease progression was observed in two patients (4%) treated with REVLIMID and dexamethasone, while sixteen (34%) patients progressed to active myeloma in the arm with no treatment. Ten out of 16 of those patients also developed bone lesions due to active myeloma. It was noted that the two patients who progressed after receiving REVLIMID and dexamethasone progressed only after stopping therapy with REVLIMID.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) 4.5% HIGHER; today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers. The data provide strong clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with resistant and refractory chronic myeloid leukemia, including those with the T315I mutation of the target protein, BCR-ABL. Click here to see more details.
Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) 4.3% LOWER; announced today the commencement of an underwritten public offering of 3,000,000 common units. Calumet also intends to grant the underwriters the option to purchase up to 450,000 additional common units.
Select Comfort Corporation (NASDAQ: SCSS) 4.1% LOWER; today announced that the company intends to offer shares of its common stock via an underwritten public offering. Piper Jaffray is acting as the sole manager for the underwritten public offering. The company plans to use the proceeds of the public offering to improve working capital and pay down debt.
FedEx (NYSE: FDX) 3.1% HIGHER; raises Q2 EPS guidance from $0.65-$0.95 to $1.10. Click here to see the full report.
Kimco Realty Corporation (NYSE: KIM) 2.8% LOWER; announced that it plans to sell 25,000,000 shares of newly issued common stock in an underwritten public offering pursuant to its effective shelf registration statement previously filed with the Securities and Exchange Commission. The underwriters will be granted a 30-day option to purchase up to an additional 3,750,000 shares to cover over-allotments, if any.
UPS (NYSE: UPS) 2.4% HIGHER; moving higher amid the FedEx raised guidance.
Diedrich Coffee, Inc.’s (NASDAQ: DDRX) 2.3% LOWER; Peet’s Coffee & Tea, Inc. (NASDAQ: PEET) announced today that in response to determination that the most recent proposal from Green Mountain Coffee Roasters, Inc. (NASDAQ: GMCR) to acquire Diedrich was superior to Peet’s most recent proposal, Peet’s will not further enhance its proposal. Peet’s further announced that it will leave in place its exchange offer to acquire Diedrich for a combination of cash and stock valued at $26.00 per share. Click here for the full report.
ModusLink Global Solutions, Inc. (NASDAQ: MLNK) 1.1% LOWER; reports Q1 EPS of $0.19, compared to ($0.41) in the same quarter last year. Revenue for the quarter was $246.68 billion, which compares to $291.42 million for Q109.
To get this report daily, visit http://www.streetinsider.com/entities/After-Hours+Movers.
You May Also Be Interested In
- Morning Movers 05/25: (GNOM) (UPI) (EJ) Higher; (DCTH) (TLB) (GENE) Lower
- Morning Movers 05/24: (GENE) (GNOM) (P) Higher; (NTAP) (PCX) (TIF) Lower
- Notable Analyst Rating Changes 05/25: (CRM) (EMN) (ITW) Upgraded; (HNZ) (COG) (LULU) Downgraded
Create E-mail Alert Related Categories
Special ReportsRelated Entities
Piper Jaffray, Keefe, Bruyette & Woods, After-Hours MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
